Bilimoria, K. Y. et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113, 3130–3136 (2008).
Else, T. et al. Adrenocortical carcinoma. Endocr. Rev. 35, 282–326 (2014).
Article CAS PubMed Google Scholar
Kebebew, E., Reiff, E., Duh, Q. Y., Clark, O. H. & McMillan, A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J. Surg. 30, 872–878 (2006).
Tella, S. H., Kommalapati, A., Yaturu, S. & Kebebew, E. Predictors of survival in adrenocortical carcinoma: an analysis from the national cancer database. J. Clin. Endocrinol. Metab. 103, 3566–3573 (2018).
Tierney, J. F. et al. National treatment practice for adrenocortical carcinoma: have they changed and have we made any progress? J. Clin. Endocrinol. Metab. 104, 5948–5956 (2019).
Kerkhofs, T. M. et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur. J. Cancer 49, 2579–2586 (2013).
McAteer, J. P., Huaco, J. A. & Gow, K. W. Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemiology, and End Results (SEER) program study. J. Pediatr. Surg. 48, 1025–1031 (2013).
Fassnacht, M. et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 115, 243–250 (2009).
Elhassan, Y. S. et al. S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. Eur. J. Endocrinol. 186, 25–36 (2021).
Article CAS PubMed PubMed Central Google Scholar
Beuschlein, F. et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J. Clin. Endocrinol. Metab. 100, 841–849 (2015).
Article CAS PubMed Google Scholar
Michalkiewicz, E. et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J. Clin. Oncol. 22, 838–845 (2004).
Article CAS PubMed Google Scholar
Loncar, Z. et al. Survival and prognostic factors for adrenocortical carcinoma: a single institution experience. BMC Urol. 15, 43 (2015).
Article PubMed PubMed Central Google Scholar
Li, P., Su, X., Zhang, X., Sun, L. & Zhang, G. Prognostic factors of adrenocortical carcinoma: experience from a Regional Medical Center in Eastern China. Int. J. Gen. Med. 16, 453–465 (2023).
Article PubMed PubMed Central Google Scholar
Lughezzani, G. et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the International Union Against Cancer-staging system: a North American validation. Eur. J. Cancer 46, 713–719 (2010).
Terzolo, M. et al. Results of the ADIUVO study, the first randomized trial on adjuvant mitotane in adrenocortical carcinoma patients. J. Endocr. Soc. 5, A166–A167 (2021).
Article PubMed Central Google Scholar
Fassnacht, M. et al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366, 2189–2197 (2012).
Article CAS PubMed Google Scholar
Fassnacht, M. et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 179, G1–G46 (2018).
Article CAS PubMed Google Scholar
Challis, B. G. et al. Familial adrenocortical carcinoma in association with Lynch syndrome. J. Clin. Endocrinol. Metab. 101, 2269–2272 (2016).
Article CAS PubMed PubMed Central Google Scholar
Gatta-Cherifi, B. et al. Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d’Etude des Tumeurs Endocrines database. Eur. J. Endocrinol. 166, 269–279 (2012).
Article CAS PubMed Google Scholar
Hampel, H. et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N. Engl. J. Med. 352, 1851–1860 (2005).
Article CAS PubMed Google Scholar
Herrmann, L. J. et al. TP53 germline mutations in adult patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 97, E476–E485 (2012).
Article CAS PubMed Google Scholar
MacFarland, S. P. et al. Management of adrenal masses in patients with Beckwith–Wiedemann syndrome. Pediatr. Blood Cancer 64, 10.1002/pbc.26432 (2017).
Article PubMed Central Google Scholar
Pinto, E. M. et al. Identification of clinical and biologic correlates associated with outcome in children with adrenocortical tumors without germline TP53 mutations: a st jude adrenocortical tumor registry and children’s oncology group study. J. Clin. Oncol. 35, 3956–3963 (2017).
Article CAS PubMed PubMed Central Google Scholar
Raymond, V. M. et al. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 98, E119–E125 (2013).
Article CAS PubMed Google Scholar
Raymond, V. M. et al. Adrenocortical carcinoma is a Lynch syndrome-associated cancer. J. Clin. Oncol. 31, 3012–3018 (2013).
Article PubMed PubMed Central Google Scholar
Seki, M. et al. Loss of normal allele of the APC gene in an adrenocortical carcinoma from a patient with familial adenomatous polyposis. Hum. Genet. 89, 298–300 (1992).
Article CAS PubMed Google Scholar
Shiroky, J. S., Lerner-Ellis, J. P., Govindarajan, A., Urbach, D. R. & Devon, K. M. Characteristics of adrenal masses in familial adenomatous polyposis. Dis. Colon Rectum 61, 679–685 (2018).
Wakatsuki, S. et al. Adrenocortical tumor in a patient with familial adenomatous polyposis: a case associated with a complete inactivating mutation of the APC gene and unusual histological features. Hum. Pathol. 29, 302–306 (1998).
Article CAS PubMed Google Scholar
Wasserman, J. D. et al. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a Children’s Oncology Group study. J. Clin. Oncol. 33, 602–609 (2015).
Article CAS PubMed PubMed Central Google Scholar
Juhlin, C. C. et al. What did we learn from the molecular biology of adrenal cortical neoplasia? From histopathology to translational genomics. Endocr. Pathol. 32, 102–133 (2021).
Article CAS PubMed Google Scholar
Grisanti, S., Cosentini, D., Sigala, S. & Berruti, A. Molecular genotyping of adrenocortical carcinoma: a systematic analysis of published literature 2019–2021. Curr. Opin. Oncol. 34, 19–28 (2022).
Article CAS PubMed Google Scholar
Else, T. et al. Adrenocortical carcinoma and succinate dehydrogenase gene mutations: an observational case series. Eur. J. Endocrinol. 177, 439–444 (2017).
Article CAS PubMed Google Scholar
Grisanti, S. et al. 29MO Germline variants NGS characterization in patients with non-syndromic adrenocortical carcinoma. ESMO Open 8, 101050 (2023).
Custodio, G. et al. Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. J. Clin. Oncol. 31, 2619–2626 (2013).
Article PubMed PubMed Central Google Scholar
Latronico, A. C. et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 86, 4970–4973 (2001).
Article CAS PubMed Google Scholar
Pinto, E. M. et al. Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arq. Bras. Endocrinol. Metab. 48, 647–650 (2004).
Ribeiro, R. C. et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc. Natl Acad. Sci. USA 98, 9330–9335 (2001).
Article CAS PubMed PubMed Central Google Scholar
Mete, O. et al. Overview of the 2022 who classification of adrenal cortical tumors. Endocr. Pathol. 33, 155–196 (2022).
Comments (0)